Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: NeuVax vaccine|DRUG: Trastuzumab|DRUG: GM-CSF
Sponsor: Cancer Insight, LLC
Collaborators: Genentech, Inc.|Sellas Life Sciences Group